Digital Contract

Concerning the patients you examined for the latest one month, please inform us the numbers of the followings: *

The number of patients you examined latest one month

The Number of patients with dyslipidaemia

Number of patients with a history of ischaemic stroke

Number of patients with (or with a history of) coronary heart disease

The number of patients receiving drug treatment for dyslipidaemia and am engaged in their treatment

Do you believe that elevated LDL cholesterol is an important cause of Coronary disease and ischaemic stroke? *

Yes

No

Uncertain

Concerning use of statin, do you have concerns related to any of the following. (More than one item can be selected) *

Increase of the risk of haemorrhagic stroke

Increase of the risk of cognitive impairment

Increase of the risk of new onset diabetes

Development of muscle disorder

Increased risk of hepatic disease

Do not have any concern

Others

Do you have concerns about lowering LDL cholesterol levels in patients with *

Haemorrhagic stroke	Yes	No	Uncertain
Ischaemic stroke	Yes	No	Uncertain
Transient ischaemic attack (TIA)	Yes	No	Uncertain
Subarachnoid haemorrhage	Yes	No	Uncertain

Do you think statins have any effect on cognitive function? *

Yes

No

Uncertain

Please indicate the percentage of patients who cannot use statins continuously due to adverse effects (such as muscle symptoms, etc.). *

0% (I have no statin-intolerant patients)

≥ 0.1 to 5%

≥ 5 to <10%

≥ 10 to < 15%

≥15 to 20%

≥20%

Please indicate your target level of LDL cholesterol after initiation of drug therapy in the following patient groups *

A history of any coronary artery disease: The target level of LDL cholesterol should be <	mg/dl
Without a history of coronary artery disease but with a history of diabetes mellitus/chronic kidney disease/ischaemic stroke/peripheral artery disease. The target level of LDL cholesterol should be <	mg/dl
Without a history of the conditions listed above: The target level of LDL cholesterol should be <	mg/dl

Do you have concerns about safety if the LDL cholesterol is below the following levels? *

20 mg/dL (0.52 mmol/L)

30 mg/dL (0.78 mmol/L)

40 mg/dL (1.03 mmol/L)

50 mg/dL (1.29 mmol/L)

60 mg/dL (1.55 mmol/L)

70 mg/dL (1.80 mmol/L)

Other value

Do you think markedly low LDL cholesterol levels affect the incidence of haemorrhagic stroke? *

Yes

No

Uncertain

How much does the LDL cholesterol level affect the risk of inducing atherosclerotic cardiovascular diseases? *

Affects the risk significantly

Affects the risk moderately

Uncertain

Affects the risk to a small extent

Does not affect the risk

Do you sometimes use "non-HDL cholesterol level" as a risk index of atherosclerotic cardiovascular diseases (ASCVD, coronary artery diseases, non-cardiogenic cerebral infarction) or a therapeutic efficacy index during your medical practice? *

non-HDL cholesterol level is not used

non-HDL cholesterol level is sometimes used as 'a risk index of ASCVD'

non-HDL cholesterol level is sometimes used as 'a therapeutic efficacy index.'

non-HDL cholesterol level is sometimes used as both 'a risk index of ASCVD' and 'a therapeutic efficacy index.'

Concerning Familial Hypercholesterolaemia (FH, one type of primary hyperlipidaemia), which best reflects your practice? *

I know about FH and have patients with FH (which was found by my diagnosis)

I know about FH and have referred patients with suspected FH to some other medical institution/physician.

I know about FH but have never seen a patient with suspected FH.

I do not know about FH.

When you make a diagnosis of FH in an adult patient (15-year-old or older), do you perform the followings? (More than one item can be selected) *

Palpation of Achilles tendon

X-ray photography of Achilles tendon

Take a family history of hyper-LDL-cholesterolaemia

Take a family history of FH

Take a family history of premature coronary artery diseases

None of the above

Do you think patients with FH have an increased incidence of ischaemic stroke? *

Yes

No

Uncertain

Do you think statins have any adverse effects on renal function? *

Yes

No

Uncertain

Do you think the lowering of LDL cholesterol reduces ASCVD events in patients with CKD? *

Yes

No

Uncertain

If yes, is LDL cholesterol lowering therapy effective for patients with any stage of CKD? *

Yes

No

Uncertain

What do you think is the target LDL cholesterol level for primary prevention of the patients with CKD? *

< 140 mg/dL (< 3.62 mmol/L)

< 120 mg/dL (< 3.10 mmol/L)

< 100 mg/dL (< 2.6 mmol/L)

< 70 mg/dL (< 1.8 mmol/L)

Medicate without setting the target LDL cholesterol level

Do you think the target LDL cholesterol level is different between patients with different CKD stage? *

Yes

No

Uncertain

Do you think there is a clinical benefit to treat CKD patients with hypertriglyceridaemia? *

Yes

No

Uncertain

How do you treat CKD patients with hypertriglyceridemia? *

Use statins

Use fibrates

Use nicotinic acid derivatives

Use n-3 polyunsaturated fatty acid

Manage through lifestyle modification without medications

Do you reduce the dose of statins in patients with CKD? *

Yes

No

Uncertain

Do you try to compensate with additional therapy when statins are used at a lower dose? *

Yes

No

Do you use any additional biomarkers for CVD risk stratification? *

Yes

No